New registry aims to uncover risks of YORVIPATH during pregnancy

NCT ID NCT07345494

Recruiting now Knowledge-focused Sponsor: Ascendis Pharma A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This registry study is collecting data from 50 women aged 15–50 who took YORVIPATH (palopegteriparatide) for hypoparathyroidism around the time of pregnancy or while breastfeeding. Researchers will monitor pregnancy complications, birth outcomes, and infant health through the first year of life. The goal is to better understand any risks to the mother, fetus, or baby from this medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Palopegteriparatide (YORVIPATH)
What this could lead to: If successful, this registry could provide crucial safety data on using YORVIPATH during pregnancy and breastfeeding, helping doctors and patients make informed treatment decisions.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove cause and effect. The small size (50 participants) and lack of a comparison group limit the strength of conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPARATHYROIDISM

Contacts and locations

Locations

Ascendis Investigational Site
RECRUITING

Morgantown, West Virginia, 26508, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.